ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.161,01
1,32%
S&P 500
5.109,09
1,20%
Dow Jones
38.284,51
0,52%
Euro vs US Dollar
1,07016
-0,24%
Bitcoin
63.832,00
-1,01%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Regeneron Pharmaceuticals Inc (REGN)

  7. Regeneron Pharmaceuticals Inc (REGN) News

REGN Regeneron Pharmaceuticals Inc

884,125
-6,56 (-0,74%)
Zuletzt aktualisiert: 21:19:09
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Regeneron Pharmaceuticals Inc REGN NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
-6,56 -0,74% 884,125 21:19:09
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
881,72 875,225 887,4794 890,68
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
25.4.202413:00GLOBERegeneron and Mammoth Biosciences Collaborate to Pursue..
24.4.202416:05GLOBERegeneron to Showcase Progress in Advancing Novel..
22.4.202423:54GLOBERegeneron to Highlight Advances in Genetic Medicine Research..
16.4.202413:18IHMARKETNEWSEricsson Soars with 66% Net Profit Growth; Live Nation Under..
11.4.202413:24IHMARKETNEWSCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’..
07.4.202422:00GLOBELinvoseltamab Pivotal Data Presented at AACR Reinforce High..
01.4.202422:05GLOBERegeneron to Report First Quarter 2024 Financial and..
25.3.202412:00GLOBERegeneron Provides Update on Biologics License Application..
13.3.202404:55PRNUSHigh School Seniors Win $1.8 Million at Regeneron Science..
13.3.202402:30GLOBEHigh School Seniors Win $1.8 Million at Regeneron Science..
11.3.202412:00GLOBEPraluent® (alirocumab) Injection Receives FDA Approval to..
08.3.202413:00GLOBEEYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet..
05.3.202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202422:14EDGAR2Form 144 - Report of proposed sale of securities
28.2.202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.2.202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.2.202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.2.202422:34EDGAR2Form 144 - Report of proposed sale of securities
26.2.202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.2.202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.2.202422:07EDGAR2Form 144 - Report of proposed sale of securities
26.2.202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.2.202421:25EDGAR2Form 144 - Report of proposed sale of securities
23.2.202422:04EDGAR2Form 144 - Report of proposed sale of securities
23.2.202407:00GLOBEDupixent® (dupilumab) sBLA Accepted for FDA Priority Review..
22.2.202423:10EDGAR2Form 144 - Report of proposed sale of securities
22.2.202422:06EDGAR2Form 144 - Report of proposed sale of securities
21.2.202413:00GLOBELinvoseltamab BLA for Treatment of Relapsed/Refractory..
20.2.202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202406:59GLOBEJapan First in the World to Approve Dupixent® (dupilumab)..
14.2.202423:08EDGAR2Form 144 - Report of proposed sale of securities
12.2.202422:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10.2.202400:19EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09.2.202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.2.202422:04EDGAR2Form 144 - Report of proposed sale of securities
09.2.202418:22EDGAR2Form 144 - Report of proposed sale of securities
08.2.202422:56EDGAR2Form 144 - Report of proposed sale of securities
08.2.202422:26EDGAR2Form 144 - Report of proposed sale of securities
08.2.202422:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.2.202422:01EDGAR2Form 3 - Initial statement of beneficial ownership of..
07.2.202423:59EDGAR2Form 144 - Report of proposed sale of securities
07.2.202423:07EDGAR2Form 144 - Report of proposed sale of securities
07.2.202422:35EDGAR2Form 144 - Report of proposed sale of securities
06.2.202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.2.202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.2.202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.2.202422:05GLOBERegeneron Announces Investor Conference Presentations

Kürzlich von Ihnen besucht

NASDAQ
REGN
Regeneron Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten